GlassScriptPhysician profile
Anthony Thomas Coluzzi
NPI 1457068405
$2,860.70
in general payments reported to CMS, 2019-2025
20 companies · $298 in 2025
The $298 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $400 · 2023: $1,807 · 2024: $356 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,460.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $741.11 | 2023-2025 | |
| Corium, LLC | $437.34 | 2022-2025 | Azstarys |
| Tris Pharma INC | $230.33 | 2022-2025 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $202.44 | 2022-2023 | Auvelity |
| Janssen Pharmaceuticals, INC | $184.82 | 2023 | Spravato |
| Almatica Pharma LLC | $133.11 | 2022-2024 | Loreev Xr, Sertraline Hcl |
| Ironshore Pharmaceuticals INC. | $122.26 | 2022-2023 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $116.33 | 2022-2023 | Hetlioz, Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $115.15 | 2022-2025 | Trintellix |
| Alkermes, INC. | $105.51 | 2022-2023 | Aristada, Lybalvi |
| Lundbeck LLC | $102.57 | 2023-2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $99.43 | 2022-2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $70.08 | 2023-2025 | Rexulti, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $68.99 | 2022-2023 | |
| Indivior INC. | $41.12 | 2024 | Sublocade |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $24.98 | 2025 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $20.00 | 2023 | Uzedy |
| Supernus Pharmaceuticals, INC. | $16.30 | 2023 | Qelbree |
| Neuronetics, INC. | $15.98 | 2022 | |
| Neos Therapeutics, LP | $12.85 | 2023 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Coluzzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.